ToxSci Advance Access originally published online on May 5, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences 80, 310-321 (2004)
Toxicological Sciences vol. 80 no. 2 © Society of Toxicology 2004; all rights reserved.
Respiratory Response to Toluene Diisocyanate Depends on Prior Frequency and Concentration of Dermal Sensitization in Mice



* Laboratories of Pneumology (Lung Toxicology),
Experimental Immunology, and
Pathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium; and
Institute of Occupational Medicine, Department of Immunotoxicology, Lodz, Poland
Received January 21, 2004; accepted April 20, 2004
Occupational asthma is the principal cause of work-related respiratory disease in the industrial world. In the absence of satisfactory models for predicting the potential of low molecular weight chemicals to cause asthma, we verified that dermal sensitization prior to intranasal challenge influences the respiratory response using toluene diisocyanate (TDI), a known respiratory sensitizer. BALB/c mice received TDI or vehicle (acetone/olive oil) on each ear on three consecutive days (days 1, 2, and 3; 0.3 or 3% TDI) or only once (day 1, 1% TDI). On day 7, the mice received similar dermal applications of vehicle or the same concentration of TDI as before ("boost"). On day 10, they received an intranasal dose of TDI (0.1%) or vehicle. Ventilatory function was monitored by whole body plethysmography for 40 min after intranasal application, and reactivity to inhaled methacholine was assessed 24 h later. Pulmonary inflammation was assessed by bronchoalveolar lavage and histology. Mice that received an intranasal dose of TDI without having received a prior dermal application of TDI did not exhibit any ventilatory response or inflammatory changes compared to vehicle controls. In contrast, mice that had received prior application(s) of TDI, even if only on day 7, exhibited the following: ventilatory responses, compatible with bronchoconstriction, immediately after intranasal application with TDI; enhanced methacholine responsiveness 24 h later; and pulmonary inflammation characterized by neutrophils. This was, however, not the case in mice that received the highest dermal amount of TDI (3% on days 1, 2, and 3). These findings suggest that respiratory response to TDI depends on prior frequency and concentration of dermal sensitization in mice.
Key Words: occupational asthma; animal model; diisocyanates; BALB/c mice; dermal sensitization; whole body plethysmography; BALF.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. K. Farraj, E. Boykin, N. Haykal-Coates, S. H. Gavett, D. Doerfler, and M. Selgrade Th2 Cytokines in Skin Draining Lymph Nodes and Serum IgE Do Not Predict Airway Hypersensitivity to Intranasal Isocyanate Exposure in Mice Toxicol. Sci., November 1, 2007; 100(1): 99 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tarkowski, J. A. J. Vanoirbeek, H. M. Vanhooren, V. D. Vooght, C. M. Mercier, J. Ceuppens, B. Nemery, and P. H. M. Hoet Immunological determinants of ventilatory changes induced in mice by dermal sensitization and respiratory challenge with toluene diisocyanate Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L207 - L214. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Selgrade, E. H. Boykin, N. Haykal-Coates, M. R. Woolhiser, C. Wiescinski, D. L. Andrews, A. K. Farraj, D. L. Doerfler, and S. H. Gavett Inconsistencies between Cytokine Profiles, Antibody Responses, and Respiratory Hyperresponsiveness following Dermal Exposure to Isocyanates Toxicol. Sci., November 1, 2006; 94(1): 108 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. CREELY, G. W. HUGHSON, J. COCKER, and K. JONES Assessing Isocyanate Exposures in Polyurethane Industry Sectors Using Biological and Air Monitoring Methods Ann. Hyg., August 1, 2006; 50(6): 609 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
J A J Vanoirbeek, G Toussaint, B Nemery, and P H M Hoet Reduced exercise capacity in a mouse model of asthma. Thorax, August 1, 2006; 61(8): 736 - 737. [Full Text] [PDF] |
||||



